Abstract |
Autologous peripheral blood stem cell transplantation (APBSCT) after intensifying conditioning is one of the post-remission therapeutic options in childhood acute myeloid leukemia (AML) patients without a matched family donor, but the optimal conditioning regimen has not been defined. This study was performed to evaluate the efficacy of a novel conditioning regimen without busulfan or total body irradiation. In total, 28 children with AML underwent APBSCT with BCVAC ( BCNU, etoposide, cytosine arabinoside and cyclophosphamide) conditioning regimen during first remission. The event-free survival rate was 71.43% for all patients and the only cause of treatment failure was relapse. Eight male patients recurred at 1-11 months (median 5 months) after APBSCT. One patient remains alive with salvage therapy after relapse. With the exception of fever, mucositis and diarrhea, no serious complications occurred during APBSCT, including veno-occlusive disease (VOD), and there was no transplantation-related mortality. One patient developed secondary MDS after APBSCT but recovered hematologically on medication. APBSCT with BCVAC conditioning was found to be a safe and effective alternative option for patients with childhood AML in first remission, without a matched family donor.
|
Authors | H J Kang, H Y Shin, H S Choi, K S Han, H S Ahn |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 33
Issue 5
Pg. 471-6
(Mar 2004)
ISSN: 0268-3369 [Print] England |
PMID | 14716339
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Antineoplastic Agents, Phytogenic
- Immunosuppressive Agents
- Cytarabine
- Etoposide
- Cyclophosphamide
- Carmustine
|
Topics |
- Acute Disease
- Adolescent
- Antineoplastic Agents, Alkylating
(administration & dosage)
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Carmustine
(administration & dosage)
- Child
- Child, Preschool
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Cytarabine
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Infant
- Infant, Newborn
- Leukemia, Myeloid
(drug therapy, epidemiology)
- Male
- Prognosis
- Recurrence
- Risk Factors
- Transplantation Conditioning
(adverse effects, methods)
|